Accenture perceives an ominous road for biopharma R&D. Successful companies will transition to an informatics-reliant R&D model, one born of evolutionary and revolutionary changes to current discovery and development methods. This future model requires an IT infrastructure that is secure yet elastic, integrating data from existing sources as well as new ones like sentiment monitoring and social networks. And to underscore the change, a new acronym: D2i, for "data to insights: the ability to convert data into decision-making, product-shaping, market/customer-influencing insights." Article